Strategic Partnerships Opportunity to expand FeNO testing reach through collaborations with healthcare networks, distributors, and diagnostics integrators in the US and international markets, leveraging NIOX VERO's non-invasive asthma biomarker capabilities.

Clinical Adoption Highlight the FeNO testing workflow advantages to clinics, hospitals, and primary care settings to drive adoption, focusing on non-invasive, rapid results, and supporting training to reduce barrier to entry.

Expansion Potential Leverage recent partner and market activity to pursue regional expansions, including partnerships with respiratory-focused distributors and broader payer coverage planning to improve access and reimbursement pathways.

Key Alliances Target strategic alliances with organizations already collaborating with NIOX (e.g., Vitalograph partnerships, AHSN network) to co-market FeNO testing, integrate with asthma management programs, and generate joint demand.

Pilot Programs Propose pilot deployments in diverse care settings to demonstrate impact on asthma diagnosis and management, collect real-world outcomes, and build a case for expanded procurement and training services.